Meeting
2022 ASCO Annual Meeting
Brigatinib in Japanese patients (pts) with ALK+ NSCLC: Final results from the phase 2 J-ALTA trial.
Authors
Pingkuan Zhang
Takeda Development Center Americas, Inc., Lexington, MA
Pingkuan Zhang , Toru Kumagai , Tatsuya Yoshida , Makoto Nishio , Ryo Toyozawa , Takashi Seto , Kazuhiko Nakagawa , Yuichiro Ohe , Nobuyuki Yamamoto , Kentarou Kudou , Takayuki Asato , Koichi Goto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03410108
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9075)
DOI
10.1200/JCO.2022.40.16_suppl.9075
Abstract #
9075
Poster Bd #
62
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.
First Author: Scott N. Gettinger
Poster
2023 ASCO Annual Meeting
SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study.
First Author: Wenfeng Fang
Poster
2022 ASCO Annual Meeting
A phase II randomized, open-labelled, multicenter study of safety and efficacy of combination brigatinib and carboplatin-pemetrexed therapy or brigatinib monotherapy as first-line treatment in patients with advanced ALK-positive non–small cell lung cancer (IFCT-2101 MASTERPROTOCOL ALK).
First Author: Michaël Duruisseaux
Poster
2021 ASCO Annual Meeting
Phase II study of brigatinib in ROS1 positive non-small cell lung cancer (NSCLC) patients previously treated with crizotinib: Barossa cohort 2.
First Author: Haruko Daga